Compare Estee Lauder Companies Inc (EL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs BIO-TECHNE Corp — how do they compare? Estee Lauder Companies Inc trades at $93.84 (market cap $34.22B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Estee Lauder Companies Inc is far larger — about 3× BIO-TECHNE Corp's market cap, and Estee Lauder Companies Inc pays the higher dividend (1.48%). Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and BIO-TECHNE Corp for 63 Days on average.
| EL | TECH | |
|---|---|---|
Market Cap | $34.22B | $11.37B |
Volume | 2,303,792 | 3,153,511 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $72.61 |
52-Week Low | $67.23 | $43.31 |
Typical Hold Time | 122 Days | 63 Days |
Enterprise Value | $39.97B | $11.40B |
Dividend Yield | 1.48% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $94.32, up 1.03% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported a net loss of $1.13 billion in 2025 despite a high gross margin of 75.5%, while 2026 forecasts show a return to profitability. Analysts maintain a consensus buy rating with a $103 price target, supported by strategic partnerships in AI and leadership changes aimed at driving growth.
The stock's outlook is cautiously optimistic, with earnings recovery and digital initiatives offering upside, but high debt levels and margin pressures pose risks. Investor sentiment is mixed amid volatile cash flows and competitive headwinds in the beauty sector.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
